The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes
Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA. Antivir Ther. 2013 Aug 15. doi: 10.3851/IMP2671. [Epub ahead of print]
Source
Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052/CNRS UMR5286, Lyon, France.
Abstract
BACKGROUND:
Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were (1) to establish the relationship between pretreatment anti-E1E2 titers and HCV RNA kinetics during PEG-IFN/RBV therapy, and (2) to examine whether the combined determination of IL28B rs12979860 and rs8099917, pretreatment IP-10 levels and/or anti-E1E2 improved the prediction of SVR.
METHODS:
Sera from 26 naive consecutive HCV patients treated with PEG-IFN/RBV for 48 weeks were analyzed. Serum anti-E1E2 titers and pretreatment IP-10 levels were measured by enzyme-linked immunosorbent assays. The IL28B variants were determined using genotyping real-time polymerase chain reaction method. Viral decline was measured at weeks (W) 4 and 12 and SVR assessed 6 months after the end of therapy.
RESULTS:
Baseline anti-E1E2 titers were correlated with HCV RNA decline at W4 and W12 and were highly predictive of SVR with 100% of patients negative for anti-E1E2 failing to achieve SVR. ROC curve analyses indicate that the best prediction of SVR (AUC 0.990) was obtained with the combination of anti-E1E2 and IP-10 levels. Predictive values were better than those obtained with IP-10 alone or in combination with IL28B variants.
CONCLUSIONS:
Pretreatment serum anti-E1E2 response predicts HCV RNA clearance kinetics and treatment outcome. The combination of anti-E1E2 and IP-10 significantly improve the prediction of treatment response. This warrants further investigation and validation on larger cohorts of patients in the context of new therapeutic strategies.